Accelerate Diagnostics Inc Net debt/EBITDA
What is the Net debt/EBITDA of Accelerate Diagnostics Inc?
The Net debt/EBITDA of Accelerate Diagnostics Inc is -2.79
What is the definition of Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA of companies in the Health Care sector on NASDAQ compared to Accelerate Diagnostics Inc
What does Accelerate Diagnostics Inc do?
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Companies with net debt/ebitda similar to Accelerate Diagnostics Inc
- Synertone Communication has Net debt/EBITDA of -2.80
- T. Rowe Price has Net debt/EBITDA of -2.80
- VOTI Detection has Net debt/EBITDA of -2.80
- Volkswagen AG has Net debt/EBITDA of -2.79
- Capital Bancorp Inc has Net debt/EBITDA of -2.79
- Tata Consultancy Services has Net debt/EBITDA of -2.79
- Accelerate Diagnostics Inc has Net debt/EBITDA of -2.79
- SPORTTOTAL AG has Net debt/EBITDA of -2.78
- Wildflower Brands has Net debt/EBITDA of -2.78
- Equus Mining has Net debt/EBITDA of -2.78
- B & S International has Net debt/EBITDA of -2.78
- Télévision Française 1 SA has Net debt/EBITDA of -2.78
- Palla Pharma has Net debt/EBITDA of -2.78